{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:13:36Z","timestamp":1783660416407,"version":"3.55.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors are increasingly incorporated into curative treatment strategies for early-stage triple-negative breast cancer. Although hematologic immune-related adverse events are rare, they may be severe and difficult to distinguish from other causes of bone marrow failure. We report a 54-year-old woman with triple-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy according to the KEYNOTE-522 regimen. After breast-conserving surgery and achievement of a pathologic complete response, she developed a rapidly progressive severe pancytopenia (grade 4 febrile neutropenia, grade 4 thrombocytopenia and grade 3 anemia) in the early postoperative period. Bone marrow biopsy showed generalized bone marrow suppression. An immune-related hematologic toxicity was suspected; high-dose corticosteroids were initiated. However, no hematologic response was observed. Further tests detected ongoing parvovirus B19 infection (positive plasma viral DNA and IgM and IgG serology). Intravenous immunoglobulin therapy was therefore initiated, resulting in rapid hematologic recovery. Pembrolizumab was discontinued, and the patient subsequently completed adjuvant radiotherapy. At a 20-month follow-up, she remained free of disease recurrence. This case highlights the importance of broad diagnostic evaluation of severe cytopenias after pembrolizumab-based chemoimmunotherapy and underscores the need to distinguish infectious bone marrow suppression from primary immune-related hematologic toxicity, as this distinction may directly influence management.<\/jats:p>","DOI":"10.3389\/fonc.2026.1834150","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:24:38Z","timestamp":1783657478000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Aplastic anemia associated with parvovirus B19 infection following neoadjuvant pembrolizumab-based chemoimmunotherapy for triple-negative breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Jan","family":"Kindl","sequence":"first","affiliation":[{"name":"Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University in Prague","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Svobodov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University in Prague","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Mat\u011bj\u016f","sequence":"additional","affiliation":[{"name":"Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University in Prague","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Zimovjanov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University in Prague","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Vo\u010dka","sequence":"additional","affiliation":[{"name":"Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University in Prague","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Kova\u0159\u00edkov\u00e1","sequence":"additional","affiliation":[{"name":"Hematology, First Department of Medicine, General University Hospital and First Faculty of Medicine, Charles University Prague","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Biel\u010dikov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University in Prague","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","year":"2022","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104473","article-title":"Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real\/GBECAM 0123 study","volume":"83","author":"de Oliveira Andrade","year":"2025","journal-title":"Breast"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll","year":"2022","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.09.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","article-title":"Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis","volume":"103","author":"Petrelli","year":"2018","journal-title":"Eur J Cancer"},{"key":"B9","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"key":"B10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1182\/blood.v48.1.63.bloodjournal48163","article-title":"Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality","volume":"48","author":"Camitta","year":"1976","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.13853","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia","volume":"172","author":"Killick","year":"2016","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra030840","article-title":"Parvovirus B19","volume":"350","author":"Young","year":"2004","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1128\/cmr.15.3.485-505.2002","article-title":"Human parvovirus B19","volume":"15","author":"Heegaard","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"B14","article-title":"Erythema infectiosum","volume-title":"Statpearls [Internet]","author":"Syed","year":"2025"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/03000605251377626","article-title":"Parvovirus B19-induced aplastic anemia following mechanical valve replacement","volume":"53","author":"Ma","year":"2025","journal-title":"J Int Med Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.nefroe.2021.11.005","article-title":"Aplastic anemia associated with parvovirus B19 in living donor kidney transplantation: experience of a reference center","volume":"41","author":"Noriega-Salas","year":"2021","journal-title":"Nefrologia (Engl Ed)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.103998","article-title":"Aplastic anemia induced by human parvovirus B19 infection in an immunocompetent adult male without prior hematological disorders: a case report","volume":"79","author":"Bhattarai","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2025.2549675","article-title":"Pure red cell aplasia due to parvovirus B19 infection and atezolizumab: case report and literature review","volume":"17","author":"Pallotta","year":"2025","journal-title":"Immunotherapy"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1057134","article-title":"Immune checkpoint inhibitor-induced aplastic anaemia: case series and large-scale pharmacovigilance analysis","volume":"14","author":"Guo","year":"2023","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1834150\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:24:39Z","timestamp":1783657479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1834150\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":19,"alternative-id":["10.3389\/fonc.2026.1834150"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1834150","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1834150"}}